March 14, 2023 06:14 PM IST

Pfizer and Seagen bet on the future of cancer drugs

The biotech company’s oncology treatments are so complex that generic drugmakers will have a hard time siphoning off revenue

Rationale behind Pfizer’s $43 billion acquisition of loss-making Seagen- unleashing guided missiles against Cancer

Albert Bourla, CEO of Pfizer, highlighted the significance of the company's $43 billion acquisition of Seagen, a biotech firm specializing in cancer therapies. Through this acquisition, Pfizer aims to accelerate cancer research and bring new solutions to patients by combining Seagen's ADC technology with its own capabilities and expertise.

Pfizer Standalone December 2022 Net Sales at Rs 621.75 crore, down 8.01% Y-o-Y

Moneycontrol Selects: Top stories this evening

Our specially curated package of the most interesting articles to help you stay at the top of your game.

Seagen could be the deal Pfizer investors have been craving

The innovative cancer drug maker is an appealing target for a pharma giant with plenty of cash to spend

Pfizer cites positive results on migraine treatment

Pfizer said the study, which has been peer-reviewed and published in the Lancet Neurology journal, showed the company's drug zavegepant had proven to be "effective in the acute treatment" of migraines and had few apparent side effects.

Pfizer names Meenakshi Nevatia as managing director

Nevatia succeeds S Sridhar who announced his early retirement in August 2022. Sridhar will be stepping down as managing director with close of business hours on March 31, 2023.

Pfizer Standalone December 2022 Net Sales at Rs 621.75 crore, down 8.01% Y-o-Y

Jairam Ramesh hits back after minister accuses Congress of pushing foreign vaccines' case during Covid

Tagging a video of Pfizer CEO Albert Bourla's encounter with a journalist in Davos, Chandrasekhar said on Twitter that the pharmaceutical company tried to bully the Indian government into accepting conditions of indemnity.

Union Minister Chandrasekhar says Pfizer tried to bully government into giving indemnity to supply COVID jab

Pfizer had sought an emergency use authorisation for its jab in December 2020 but withdrew the proposal in February 2021 after failing to meet the drug regulator’s demand for a local safety study

Dr Reddy's acquires trademark rights for Pfizer's breast cancer drug

The drug will be retailed in the Indian market at an 85 percent reduction from the current MRP to increase affordability and access, the pharma company has said

All you need to know about Paxlovid, the most promising COVID-19 drug

US-based Pfizer has signed a licensing agreement for Paxlovid with 30 drugmakers globally, including 19 Indian companies. Hetero and Zenara have said they received regulatory approvals for their versions of Paxlovid

Pfizer India employees to get 12-week paternity leave. Check details

Paternity leaves are increasingly becoming the norm at many workplaces, breaking the stereotype of childcare primarily being the mother's responsibility.

Top 10 trading ideas for next 3-4 weeks as selling spree gathers momentum

The selling can be extended in the coming sessions with support at 18,100-18,000 levels, however, on the higher side, the index may face hurdles at 18,500-18,700 levels if it holds these supports

Top 10 trading ideas by experts for next 3-4 weeks as broader markets participation likely to increase

The momentum is intact and the Friday's correction is on expected lines given the consistent uptrend in the past. Hence, once the current consolidation ends, the Nifty50 is expected to resume upward journey once again towards 18,900-19,000 levels in coming days, with crucial supports at 18,500-18,300, experts said

Glenmark Pharma reaches settlement agreement with Pfizer for Axitinib Tablets

According to sales data for the 12‐month period ending September 2022, the Inlyta Tablets, 1 mg and 5 mg, achieved annual sales of approximately $644.5 million

Hold Pfizer; target of Rs 4505: ICICI Direct

ICICI Direct recommended hold rating on Pfizer with a target price of Rs 4505 in its research report dated November 17, 2022.

Top 10 trading ideas for next 3-4 weeks in a market moving largely sideways

Breaching either side of 18,200-18,450 range can give some kind of direction to the market in the coming days, but having a monthly expiry and FOMC minutes scheduled this week, volatility and consolidation is at the top before any kind of big move on either side of range

Pfizer/BioNTech Omicron shot shows immune response against BQ.1.1 subvariant

Antibody levels against the variant rose nearly 9 times in older adults, aged 55 and above, who received the Omicron shot compared to a 2-fold increase in participants with the original shot, according to data posted on the online archive bioRxiv.

Pfizer Standalone September 2022 Net Sales at Rs 637.47 crore, up 0.19% Y-o-Y

US stocks turn lower as hot jobs data signals aggressive Fed

The S&P 500 fell 0.5% as of 12:50 p.m. Eastern. It had been up as much as 1% shortly after trading opened. The Dow Jones Industrial Average fell 129 points, or 0.4%, to 32,604 and the Nasdaq fell 0.8%.

Pfizer rides Paxlovid sales to better-than-expected quarter

The pill treatment Paxlovid brought in $7.5 billion in sales in the quarter and has generated more than $17 billion so far this year.

Top 10 trading ideas for next 3-4 weeks with bulls ready to reign Dalal Street

MCX India has witnessed a breakout of a bullish double bottom pattern formation on the longer time frame while on the daily chart; it has given a breakout of a bullish Inverse Head & Shoulder pattern with huge volume.

Pfizer says COVID-19 vaccine will cost $110-$130 per dose

More than 375 million doses of the original vaccine, which Pfizer developed with the German drugmaker BioNTech, have been distributed in the U.S., according to the Centers for Disease Control and Prevention.

Top 10 trading ideas for next 3-4 weeks as volatility rules Dalal Street

Healthcare Global Enterprises has broken out from the horizontal channel on the weekly charts. Price breakout is accompanied by jump in volumes. It is placed above all important moving averages, which indicates bullish trend on all time frames.